Pharmaceutical Technology
NOVEMBER 13, 2024
Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported.
Bio Pharma Dive
NOVEMBER 13, 2024
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab over Keytruda.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Worldwide Clinical Trials
NOVEMBER 13, 2024
By; Brooke Kaplan, Director, People Partner- HR Compliance & Human Capital Initiatives In April 2007, at 19 years old, I was a sophomore at the University of Maryland. I had always been relatively healthy, exercised recreationally, and worked part-time at the campus gym. I’d just returned from spring break at Disney World with my boyfriend (now husband), Zak, and we were gearing up for the Jewish holiday of Passover.
Bio Pharma Dive
NOVEMBER 13, 2024
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rethinking Clinical Trials
NOVEMBER 13, 2024
In this Friday’s PCT Grand Rounds, Kit Delgado of the University of Pennsylvania will present “Pragmatic Randomized Trial of Smartphone-Based Nudges to Reduce Distracted Driving Among US Auto Insurance Customers.” The Grand Rounds session will be held on Friday, November 15, 2024, at 1:00 pm eastern. Delgado is an associate professor of emergency medicine and epidemiology at the University of Pennsylvania and the director of the Penn Medicine Nudge Unit, which “designs an
Bio Pharma Dive
NOVEMBER 13, 2024
The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune system.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
NOVEMBER 13, 2024
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.
Pharmaceutical Technology
NOVEMBER 13, 2024
The company plans to discontinue the study after the combination therapy failed to meet the primary endpoint in the Phase III trial.
Bio Pharma Dive
NOVEMBER 13, 2024
The genetic testing firm will also close its drug development arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.
Pharmaceutical Technology
NOVEMBER 13, 2024
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease treatment.
Fierce Pharma
NOVEMBER 13, 2024
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years fkansteiner Wed, 11/13/2024 - 14:37
Pharmaceutical Technology
NOVEMBER 13, 2024
Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it be mastered?
XTalks
NOVEMBER 13, 2024
Merck KGaA recently shared positive results from its Phase III MANEUVER trial on pimicotinib, an investigational oral therapy for tenosynovial giant cell tumor (TGCT). TGCT is a rare, aggressive joint condition caused by overactive colony-stimulating factor 1 (CSF-1). A generally non-cancerous growth that forms in the tissue lining the joints, tendons or fluid-filled sacs around joints, TGCT often leads to abnormal joint tissue growth, painful swelling and stiffness.
Pharmaceutical Technology
NOVEMBER 13, 2024
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
NOVEMBER 13, 2024
First patient dosed in phase 1b trial of MB310 therapy
Pharmaceutical Technology
NOVEMBER 13, 2024
Ontada has entered into a strategic partnership with health data platform Datavant to enable quick access to oncology insights.
Fierce Pharma
NOVEMBER 13, 2024
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1), AstraZeneca is touting a trial result that could allow the company and | Four years after scoring an FDA approval to treat children with NF1, AstraZeneca says its Merck-partnered Koselugo has shown promise in adults.
Bio Pharma Dive
NOVEMBER 13, 2024
The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead of offering upfront discounts.
Pharma Times
NOVEMBER 13, 2024
New long-term partnership to address neurological disorder treatments
pharmaphorum
NOVEMBER 13, 2024
AI technology is revolutionising the field of surgery by aiding in more precise and accurate diagnoses. Learn how AI is transforming the future of healthcare.
XTalks
NOVEMBER 13, 2024
GE HealthCare’s SIGNA MAGNUS 3.0T magnetic resonance imaging (MRI) system, a head-only MRI scanner designed specifically for advanced neuroimaging, has been cleared by the US Food and Drug Administration (FDA). Unlike traditional whole-body MRI scanners, the SIGNA MAGNUS is tailored exclusively for imaging the brain and central nervous system (CNS), focusing on capturing intricate details required in neuroscience and clinical diagnostics.
pharmaphorum
NOVEMBER 13, 2024
Explore the implications of China's Anti-Espionage Law on pharmaceutical supply chains and learn how businesses can navigate new risks effectively.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Outsourcing Pharma
NOVEMBER 13, 2024
Driven by the effects of the COVID-19 pandemic, the market for decentralized clinical trials has seen a push that will lead it to more than triple in size within the next decade.
pharmaphorum
NOVEMBER 13, 2024
London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US, says MedCity report
Outsourcing Pharma
NOVEMBER 13, 2024
A recent Lindus Health survey emphasizes the importance of patient-centered designs in clinical trials, particularly highlighting how telehealth options could improve accessibility and convenience for participants.
pharmaphorum
NOVEMBER 13, 2024
BioNTech buys Biotheus and its Keytruda rival for $950m Phil.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
NOVEMBER 13, 2024
Driven by the effects of the COVID-19 pandemic, the market for decentralized clinical trials has seen a push that will lead it to more than triple in size within the next decade.
pharmaphorum
NOVEMBER 13, 2024
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density
Outsourcing Pharma
NOVEMBER 13, 2024
Traditional clinical trials usually rely on several physical trial sites to recruit and monitor patients.
pharmaphorum
NOVEMBER 13, 2024
Former Babylon Health founder and CEO Ali Parsa is back with new venture Quadrivia and Qu, an AI tool to support clinician decision-making
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
246 
Let's personalize your content